Monday, August 12, 2013 12:23:29 AM
ViorraTM has completed and passed irritation, allergic reaction, oral toxicity and three year stability studies. ViorraTM has completed an Open Label Clinical Pilot Trial to evaluate the safety and efficacy of the product. Pre and post-menopausal women with pre-diagnosed sexual function disorder for the past five years tested ViorraTM. There were no adverse data reported during the study and collectively the subjects reported: Less genital pain during intercourse, more sexual attempts with their partner, increase in vaginal lubrication, higher incidence of orgasm, increased desire to engage in sexual activity and an overall increase in sexual satisfaction.
FEATURED Nightfood Signs Letter of Intent to Acquire Los Angeles Cooking School, Integrating Automation and Robotics with World-Class Culinary Training • Oct 1, 2024 8:30 AM
FEATURED ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • Oct 1, 2024 7:00 AM
Integrated Ventures, Inc Reports Total 2024 Revenues Of $5,863,935 vs $3,862,849 for 2023. • INTV • Oct 1, 2024 9:00 AM
Element79 Gold Corp secures loi for launching tailings reprocessing business in Arequipa, Peru • ELMGF • Oct 1, 2024 6:38 AM
BARRON'S COVE to Premier at the Hamptons International Film Festival • APHP • Sep 30, 2024 2:56 PM
Lingerie Fighting Championships Signs Broadcast Deal With Maybacks Global Entertainment • BOTY • Sep 26, 2024 9:00 AM